GLAND PHARMA SWOT , DISCLAMER INH000013174

Strengths Strong injectable-focused business model with global presence across the US, Europe, Canada, Australia, and 60+ countries. One of the largest and fastest-growing injectable pharma companies with 89+ product SKUs across multiple therapeutic areas. Weaknesses Low ROE compared with top pharma peers; return ratios remain moderate despite scale. Historical sales growth has been relatively slow over the past five years. Revenue concentration in the US injectable market increases dependency risk. Promoter holding has decreased over the last 3 years, and FII/FPI shareholding decline is also a concern. Opportunities Expansion in complex injectables, biosimilars, and CDMO business can drive future growth New product launches and ANDA pipeline support long-term export growth Growing demand in regulated markets like the US and Europe Operational turnaround and better profitability from acquired businesses can improve margins Threats USFDA regulatory risk and compliance issues can significantly affect exports Pricing pressure in generic injectable pharma can reduce margins Competition from large global pharma manufacturers Currency fluctuations and geopolitical risks, including global supply-chain disruptions Disclaimer (INH000013174) Disclaimer: This analysis is for educational and informational purposes only and should not be considered as investment advice, stock recommendation, or solicitation to buy/sell securities. Investments in the stock market are subject to market risks. Please consult your financial advisor before making any investment decision. SEBI Registered Research Analyst Disclosure: Registration No.: INH000013174 Past performance is not indicative of future results. Please do your own research before investing.